Skip to main content
SpringerLink
Log in

Pharmacogenetic Screening for Polymorphisms in Drug-Metabolizing Enzymes and Drug Transporters in a Dutch Population

  • Original Research Article
  • Published:
Molecular Diagnosis & Therapy Aims and scope Submit manuscript

Abstract

Background: A possible explanation for the wide interindividual variability in toxicity and efficacy of drug therapy is variation in genes encoding drug-metabolizing enzymes and drug transporters. The allelic frequency of these genetic variants, linkage disequilibrium (LD), and haplotype of these polymorphisms are important parameters in determining the genetic differences between patients. The aim of this study was to explore the frequencies of polymorphisms in drug-metabolizing enzymes (CYP1A1, CYP2C9, CYP2C19, CYP3A4, CYP2D6, CYP3A5, DPYD, UGT1A1, GSTM1, GSTP1, GSTT1) and drug transporters (ABCB1[MDR1] and ABCC2[MRP2]), and to investigate the LD and perform haplotype analysis of these polymorphisms in a Dutch population.

Methods: Blood samples were obtained from 100 healthy volunteers and genomic DNA was isolated and amplified by PCR. The amplification products were sequenced and analyzed for the presence of polymorphisms by sequence alignment.

Results: In the study population, we identified 13 new single nucleotide polymorphisms (SNPs) in Caucasians and three new SNPs in non-Caucasians, in addition to previously recognized SNPs. Three of the new SNPs were found within exons, of which two resulted in amino acid changes (A428T in CYP2C9 resulting in the amino acid substitution D143V; and C4461T in ABCC2 in a non-Caucasian producing the amino acid change T1476M). Several LDs and haplotypes were found in the Caucasian individuals.

Conclusion: In this Dutch population, the frequencies of 16 new SNPs and those of previously recognized SNPs were determined in genes coding for drug-metabolizing enzymes and drug transporters. Several LDs and haplotypes were also inferred. These data are important for further research to help explain the interindividual pharmacokinetic and pharmacodynamic variability in response to drug therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Fig. 1
Table II
Fig. 2
Table III
Table IV
Fig. 3
Table V

Similar content being viewed by others

References

  1. Daly AK. Pharmacogenetics of the major polymorphic metabolizing enzymes. Fundam Clin Pharmacol 2003 Feb; 17(1): 27–41

    Article  PubMed  CAS  Google Scholar 

  2. Kerb R, Hoffmeyer S, Brinkmann U. ABC drug transporters: hereditary polymorphisms and pharmacological impact in MDR1, MRP1 and MRP2. Pharmacogenomics 2001 Feb; 2(1): 51–64

    Article  PubMed  CAS  Google Scholar 

  3. Bartsch H, Nair U, Risch A, et al. Genetic polymorphism of CYP genes, alone or in combination, as a risk modifier of tobacco-related cancers. Cancer Epidemiol Biomarkers Prev 2000 Jan; 9(1): 3–28

    PubMed  CAS  Google Scholar 

  4. Dunning AM, Healey CS, Pharoah PD, et al. A systematic review of genetic polymorphisms and breast cancer risk. Cancer Epidemiol Biomarkers Prev 1999 Oct; 8(10): 843–54

    PubMed  CAS  Google Scholar 

  5. Human cytochrome P450 (CYP) allele nomenclature committee [online]. Available from URL: http://www.imm.ki.se/CYPalleles/ [Accessed 2006 May 8]

  6. ABC-transporter genes [online]. Available from URL: http://www.gene.ucl.ac.uk/nomenclature/genefamily/abc.html [Accessed 2006 May 8]

  7. Dai D, Tang J, Rose R, et al. Identification of variants of CYP3A4 and characterization of their abilities to metabolize testosterone and chlorpyrifos. J Pharmacol Exp Ther 2001 Dec; 299(3): 825–31

    PubMed  CAS  Google Scholar 

  8. Eiselt R, Domanski TL, Zibat A, et al. Identification and functional characterization of eight CYP3A4 protein variants. Pharmacogenetics 2001 Jul; 11(5): 447–58

    Article  PubMed  CAS  Google Scholar 

  9. vonAhsen N, Richter M, Grupp C, et al. No influence of the MDR-1 C3435T polymorphism or a CYP3A4 promoter polymorphism (CYP3A4-V allele) on dose-adjusted cyclosporin A trough concentrations or rejection incidence in stable renal transplant recipients. Clin Chem 2001 Jun; 47(6): 1048–52

    Google Scholar 

  10. Anglicheau D, Thervet E, Etienne I, et al. CYP3A5 and MDR1 genetic polymorphisms and cyclosporine pharmacokinetics after renal transplantation. Clin Pharmacol Ther 2004 May; 75(5): 422–33

    Article  PubMed  CAS  Google Scholar 

  11. Plasschaert SL, Groninger E, Boezen M, et al. Influence of functional polymorph-isms of the MDR1 gene on vincristine pharmacokinetics in childhood acute lymphoblastic leukemia. Clin Pharmacol Ther 2004 Sep; 76(3): 220–9

    Article  PubMed  CAS  Google Scholar 

  12. The European agency for the evaluation of medicinal products. Note for guidance on good clinical practice [online]. Available from URL: http://www.emea.eu.int/pdfs/human/ich/013595en.pdf [Accessed 2006 May 24]

  13. Boom R, Sol CJ, Salimans MM, et al. Rapid and simple method for purification of nucleic acids.J Clin Microbiol 1990 Mar; 28(3): 495–503

    PubMed  CAS  Google Scholar 

  14. Cascorbi I, Brockmoller J, Roots I. A C4887A polymorphism in exon 7 of human CYP1A1: population frequency, mutation linkages, and impact on lung cancer susceptibility. Cancer Res 1996 Nov 1; 56(21): 4965–9

    PubMed  CAS  Google Scholar 

  15. Sullivan-Klose TH, Ghanayem BI, Bell DA, et al. The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics 1996 Aug; 6(4): 341–9

    Article  PubMed  CAS  Google Scholar 

  16. Goldstein JA, Blaisdell J. Genetic tests which identify the principal defects in CYP2C19 responsible for the polymorphism in mephenytoin metabolism. Methods Enzymol 1996; 272: 210–8

    Article  PubMed  CAS  Google Scholar 

  17. Sata F, Sapone A, Elizondo G, et al. CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12: evidence for an allelic variant with altered catalytic activity. Clin Pharmacol Ther 2000 Jan; 67(1): 48–56

    Article  PubMed  CAS  Google Scholar 

  18. vanSchaik RH, van der Heiden I, van den Anker JN, et al. CYP3A5 variant allele frequencies in Dutch Caucasians. Clin Chem 2002 Oct; 48(10): 1668–71

    PubMed  Google Scholar 

  19. Schur BC, Bjerke J, Nuwayhid N, et al. Genotyping of cytochrome P450 2D6*3 and *4 mutations using conventional PCR. Clin Chim Acta 2001 Jun; 308(1-2): 25–31

    Article  PubMed  CAS  Google Scholar 

  20. vanKuilenburg AB, Haasjes J, Richel DJ, et al. Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: identification of new mutations in the DPD gene. Clin Cancer Res 2000 Dec; 6(12): 4705–12

    PubMed  Google Scholar 

  21. Huang CS, Luo GA, Huang ML, et al. Variations of the bilirubin uridine-diphosphoglucuronosyl transferase 1A1 gene in healthy Taiwanese. Pharmacogenetics 2000 Aug; 10(6): 539–44

    Article  PubMed  CAS  Google Scholar 

  22. Sreelekha TT, Ramadas K, Pandey M, et al. Genetic polymorphism of CYP1A1, GSTM1 and GSTT1 genes in Indian oral cancer. Oral Oncol 2001 Oct; 37(7): 593–8

    Article  PubMed  CAS  Google Scholar 

  23. Jeronimo C, Varzim G, Henrique R, et al. I105V polymorphism and promoter methylation of the GSTP1 gene in prostate adenocarcinoma. Cancer Epidemiol Biomarkers Prev 2002 May; 11(5): 445–50

    PubMed  CAS  Google Scholar 

  24. Schwab M, Eichelbaum M, Fromm MF. Genetic polymorphisms of the human MDR1 drug transporter. Annu Rev Pharmacol Toxicol 2003; 43: 285–307

    Article  PubMed  CAS  Google Scholar 

  25. Hoffmeyer S, Burk O, von Richter O, et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A 2000 Mar 28; 97(7): 3473–8

    Article  PubMed  CAS  Google Scholar 

  26. Kim RB, Leake BF, Choo EF, et al. Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther 2001 Aug; 70(2): 189–99

    Article  PubMed  CAS  Google Scholar 

  27. Ito S, Ieiri I, Tanabe M, et al. Polymorphism of the ABC transporter genes, MDR1, MRP1 and MRP2/cMOAT, in healthy Japanese subjects. Pharmacogenetics 2001 Mar; 11(2): 175–84

    Article  PubMed  CAS  Google Scholar 

  28. Scordo MG, Aklillu E, Yasar U, et al. Genetic polymorphism of cytochrome P450 2C9 in a Caucasian and a black African population. Br J Clin Pharmacol 2001 Oct; 52(4): 447–50

    Article  PubMed  CAS  Google Scholar 

  29. Scordo MG, Caputi AP, D’Arrigo C, et al. Allele and genotype frequencies of CYP2C9, CYP2C19 and CYP2D6 in an Italian population. Pharmacol Res 2004 Aug; 50(2): 195–200

    Article  PubMed  CAS  Google Scholar 

  30. Yasar U, Eliasson E, Dahl ML, et al. Validation of methods for CYP2C9 genotyp-ing: frequencies of mutant alleles in a Swedish population. Biochem Biophys Res Commun 1999 Jan 27; 254(3): 628–31

    Article  PubMed  CAS  Google Scholar 

  31. Lee CR, Goldstein JA, Pieper JA. Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data. Pharmacogenetics 2002 Apr; 12(3): 251–63

    Article  PubMed  CAS  Google Scholar 

  32. Gaikovitch EA, Cascorbi I, Mrozikiewicz PM, et al. Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian population. Eur J Clin Pharmacol 2003 Aug; 59(4): 303–12

    Article  PubMed  CAS  Google Scholar 

  33. Goldstein JA, Ishizaki T, Chiba K, et al. Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations. Pharmacogenetics 1997 Feb; 7(1): 59–64

    Article  PubMed  CAS  Google Scholar 

  34. Hoskins JM, Shenfield GM, Gross AS. Relationship between proguanil metabolic ratio and CYP2C19 genotype in a Caucasian population. Br J Clin Pharmacol 1998 Nov; 46(5): 499–504

    Article  PubMed  CAS  Google Scholar 

  35. Xie HG, Stein CM, Kim RB, et al. Allelic, genotypic and phenotypic distributions of S-mephenytoin 4′-hydroxylase (CYP2C19) in healthy Caucasian populations of European descent throughout the world. Pharmacogenetics 1999 Oct; 9(5): 539–49

    Article  PubMed  CAS  Google Scholar 

  36. Ball SE, Scatina J, Kao J, et al. Population distribution and effects on drug metabolism of a genetic variant in the 5′ promoter region of CYP3A4. Clin Pharmacol Ther 1999 Sep; 66(3): 288–94

    Article  PubMed  CAS  Google Scholar 

  37. Hamzeiy H, Vahdati-Mashhadian N, Edwards HJ, et al. Mutation analysis of the human CYP3A4 gene 5′ regulatory region: population screening using non-radioactive SSCP. Mutat Res2002 Mar 20; 500(1-2): 103–10

    Article  PubMed  CAS  Google Scholar 

  38. vanSchaik RH, deWildt SN, van Iperen NM, et al. CYP3A4-V polymorphism detection by PCR-restriction fragment length polymorphism analysis and its allelic frequency among 199 Dutch Caucasians. Clin Chem 2000 Nov; 46(11): 1834–6

    PubMed  Google Scholar 

  39. Walker AH, Jaffe JM, Gunasegaram S, et al. Characterization of an allelic variant in the nifedipine-specific element of CYP3A4: ethnic distribution and implications for prostate cancer risk. Mutations in brief no. 191. Online. Hum Mutat 1998; 12(4): 289

    PubMed  CAS  Google Scholar 

  40. Garcia-Martin E, Martinez C, Pizarro RM, et al. CYP3A4 variant alleles in white individuals with low CYP3A4 enzyme activity. Clin Pharmacol Ther 2002 Mar; 71(3): 196–204

    Article  PubMed  CAS  Google Scholar 

  41. Lee SJ, Usmani KA, Chanas B, et al. Genetic findings and functional studies of human CYP3A5 single nucleotide polymorphisms in different ethnic groups. Pharmacogenetics 2003 Aug; 13(8): 461–72

    Article  PubMed  CAS  Google Scholar 

  42. Xie HG, Wood AJ, Kim RB, et al. Genetic variability in CYP3A5 and its possible consequences. Pharmacogenomics 2004 Apr; 5(3): 243–72

    Article  PubMed  CAS  Google Scholar 

  43. vanKuilenburg AB, Muller EW, Haasjes J, et al. Lethal outcome of a patient with a complete dihydropyrimidine dehydrogenase (DPD) deficiency after administration of 5-fluorouracil: frequency of the common IVS14+1G>A mutation causing DPD deficiency. Clin Cancer Res 2001 May; 7(5): 1149–53

    PubMed  Google Scholar 

  44. Lampe JW, Bigler J, Horner NK, et al. UDP-glucuronosyltransferase (UGT1A1*28 and UGT1A6*2) polymorphisms in Caucasians and Asians: relationships to serum bilirubin concentrations. Pharmacogenetics 1999 Jun; 9(3): 341–9

    Article  PubMed  CAS  Google Scholar 

  45. Beutler E, Gelbart T, Demina A. Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism? Proc Natl Acad Sci U S A 1998 Jul 7; 95(14): 8170–4

    Article  PubMed  CAS  Google Scholar 

  46. Iyer L, Hall D, Das S, et al. Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1 A1 promoter polymorphism. Clin Pharmacol Ther 1999 May; 65(5): 576–82

    Article  PubMed  CAS  Google Scholar 

  47. Fertrin KY, Goncalves MS, Saad ST, et al. Frequencies of UDP-glucuronosyltransferase 1 (UGT1A1) gene promoter polymorphisms among distinct ethnic groups from Brazil. Am J Med Genet 2002 Mar 1; 108(2): 117–9

    Article  PubMed  CAS  Google Scholar 

  48. Viezzer C, Norppa H, Clonfero E, et al. Influence of GSTM1, GSTT1, GSTP1, and EPHX gene polymorphisms on DNA adduct level and HPRT mutant frequency in coke-oven workers. Mutat Res 1999 Dec 17; 431(2): 259–69

    Article  PubMed  CAS  Google Scholar 

  49. Krajinovic M, Labuda D, Richer C, et al. Susceptibility to childhood acute lymphoblastic leukemia: influence of CYP1A1, CYP2D6, GSTM1, and GSTT1 genetic polymorphisms. Blood 1999 Mar 1; 93(5): 1496–501

    PubMed  CAS  Google Scholar 

  50. Garte S, Gaspari L, Alexandrie AK, et al. Metabolic gene polymorphism frequencies in control populations. Cancer Epidemiol Biomarkers Prev 2001 Dec; 10(12): 1239–48

    PubMed  CAS  Google Scholar 

  51. Ballerini S, Bellincampi L, Bernardini S, et al. Analysis of GSTP1-1 polymorphism using real-time polymerase chain reaction. Clin Chim Acta 2003 Mar; 329(1-2): 127–32

    Article  PubMed  CAS  Google Scholar 

  52. Kroetz DL, Pauli-Magnus C, Hodges LM, et al. Sequence diversity and haplotype structure in the human ABCB1 (MDR1, multidrug resistance transporter) gene. Pharmacogenetics 2003 Aug; 13(8): 481–94

    Article  PubMed  CAS  Google Scholar 

  53. Cascorbi I, Gerloff T, Johne A, et al. Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin Pharmacol Ther 2001 Mar; 69(3): 169–74

    Article  PubMed  CAS  Google Scholar 

  54. Furuno T, Landi MT, Ceroni M, et al. Expression polymorphism of the blood-brain barrier component P-glycoprotein (MDR1) in relation to Parkinson’s disease. Pharmacogenetics 2002 Oct; 12(7): 529–34

    Article  PubMed  CAS  Google Scholar 

  55. Gerloff T, Schaefer M, Johne A, et al. MDR1 genotypes do not influence the absorption of a single oral dose of 1 mg digoxin in healthy white males. Br J Clin Pharmacol 2002 Dec; 54(6): 610–6

    Article  PubMed  CAS  Google Scholar 

  56. Schaeffeler E, Eichelbaum M, Brinkmann U, et al. Frequency of C3435T polymorphism of MDR1 gene in African people. Lancet 2001 Aug 4; 358(9279): 383–4

    Article  PubMed  CAS  Google Scholar 

  57. Drozdzik M, Bialecka M, Mysliwiec K, et al. Polymorphism in the P-glycoprotein drug transporter MDR1 gene: a possible link between environmental and genetic factors in Parkinson’s disease. Pharmacogenetics 2003 May; 13(5): 259–63

    Article  PubMed  CAS  Google Scholar 

  58. Fukushima-Uesaka H, Saito Y, Watanabe H, et al. Haplotypes of CYP3A4 and their close linkage with CYP3A5 haplotypes in a Japanese population. Hum Mutat 2004 Jan; 23(1): 100

    Article  PubMed  Google Scholar 

  59. Collie-Duguid ES, Etienne MC, Milano G, et al. Known variant DPYD alleles do not explain DPD deficiency in cancer patients. Pharmacogenetics 2000 Apr; 10(3): 217–23

    Article  PubMed  CAS  Google Scholar 

  60. Johnson MR, Wang K, Diasio RB. Profound dihydropyrimidine dehydrogenase deficiency resulting from a novel compound heterozygote genotype. Clin Cancer Res 2002 Mar; 8(3): 768–74

    PubMed  CAS  Google Scholar 

  61. vanKuilenburg AB. Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil. Eur J Cancer 2004 May; 40(7): 939–50

    Article  PubMed  Google Scholar 

  62. Marcuello E, Altes A, Menoyo A, et al. UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer. Br J Cancer 2004 Aug 16; 91(4): 678–82

    PubMed  CAS  Google Scholar 

  63. Ando Y, Saka H, Ando M, et al. Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res 2000 Dec 15; 60(24): 6921–6

    PubMed  CAS  Google Scholar 

  64. Hitzl M, Drescher S, van der Banti KH, et al. The C3435T mutation in the human MDR1 gene is associated with altered efflux of the P-glycoprotein substrate rhodamine 123 from CD56+ natural killer cells. Pharmacogenetics 2001 Jun; 11(4): 293–8

    Article  PubMed  CAS  Google Scholar 

  65. Sakaeda T, Nakamura T, Horinouchi M, et al. MDR1 genotype-related pharma-cokinetics of digoxin after single oral administration in healthy Japanese subjects. Pharm Res 2001 Oct; 18(10): 1400–4

    Article  PubMed  CAS  Google Scholar 

  66. Saitoh A, Singh KK, Powell CA, et al. An MDR1-3435 variant is associated with higher plasma nelfinavir levels and more rapid virologic response in HIV-1 infected children. AIDS 2005 Mar 4; 19(4): 371–80

    Article  PubMed  CAS  Google Scholar 

  67. Tang K, Ngoi SM, Gwee PC, et al. Distinct haplotype profiles and strong linkage disequilibrium at the MDR1 multidrug transporter gene locus in three ethnic Asian populations. Pharmacogenetics 2002 Aug; 12(6): 437–50

    Article  PubMed  CAS  Google Scholar 

  68. Tang K, Wong LP, Lee EJ, et al. Genomic evidence for recent positive selection at the human MDR1 gene locus. Hum Mol Genet 2004 Apr 15; 13(8): 783–97

    Article  PubMed  CAS  Google Scholar 

  69. Sai K, Kaniwa N, Itoda M, et al. Haplotype analysis of ABCB1/MDR1 blocks in a Japanese population reveals genotype-dependent renal clearance of irinotecan. Pharmacogenetics 2003 Dec; 13(12): 741–57

    Article  PubMed  CAS  Google Scholar 

  70. Allabi AC, Horsmans Y, Issaoui B, et al. Single nucleotide polymorphisms of ABCB1 (MDR1) gene and distinct haplotype profile in a West Black African population. Eur J Clin Pharmacol 2005 Apr; 61(2): 97–102

    Article  PubMed  CAS  Google Scholar 

  71. Wada M, Toh S, Taniguchi K, et al. Mutations in the canilicular multispecific organic anion transporter (cMOAT) gene, a novel ABC transporter, in patients with hyperbilirubinemia II/Dubin-Johnson syndrome. Hum Mol Genet 1998 Feb; 7(2): 203–7

    Article  PubMed  CAS  Google Scholar 

  72. Toh S, Wada M, Uchiumi T, et al. Genomic structure of the canalicular multispecific organic anion-transporter gene (MRP2/cMOAT) and mutations in the ATP-binding-cassette region in Dubin-Johnson syndrome. Am J Hum Genet 1999 Mar; 64(3): 739–46

    Article  PubMed  CAS  Google Scholar 

  73. Itoda M, Saito Y, Soyama A, et al. Polymorphisms in the ABCC2 (cMOAT/ MRP2) gene found in 72 established cell lines derived from Japanese individuals: an association between single nucleotide polymorphisms in the 5′-untranslated region and Exon 28. Drug Metab Dispos 2002 Apr; 30(4): 363–4

    Article  PubMed  CAS  Google Scholar 

  74. Mor-Cohen R, Zivelin A, Rosenberg N, et al. Identification and functional analysis of two novel mutations in the multidrug resistance protein 2 gene in Israeli patients with Dubin-Johnson syndrome. J Biol Chem 2001 Oct 5; 276(40): 36923–30

    Article  PubMed  CAS  Google Scholar 

  75. Kuwano M, Toh S, Uchiumi T, et al. Multidrug resistance-associated protein subfamily transporters and drug resistance. Anticancer Drug Des 1999 Apr; 14(2): 123–31

    PubMed  CAS  Google Scholar 

  76. Materna V, Lage H. Homozygous mutation Arg768Trp in the ABC-transporter encoding gene MRP2/cMOAT/ABCC2 causes Dubin-Johnson syndrome in a Caucasian patient. J Hum Genet 2003; 48(9): 484–6

    Article  PubMed  CAS  Google Scholar 

  77. Hulot JS, Villard E, Maguy A, et al. A mutation in the drug transporter gene ABCC2 associated with impaired methotrexate elimination. Pharmacogenet Genomics 2005 May; 15(5): 277–85

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

This work has been supported in part by a grant from Aventis Pharma BV, The Netherlands.

The authors have no conflicts of interest that are directly relevant to the content of this study.

Author information

Authors and Affiliations

  1. Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute/Slotervaart Hospital, Louwesweg 6, Amsterdam, 1066 EC, The Netherlands

    T. M. Bosch PhD PharmD & J. H. Beijnen

  2. Medical Oncology Department, Antoni van Leeuwenhoek Hospital/The Netherlands Cancer Institute, Amsterdam, The Netherlands

    V. D. Doodeman & J. H. M. Schellens

  3. Department of Molecular Biology, Slotervaart Hospital, Amsterdam, The Netherlands

    P. H. M. Smits

  4. Department of Biomedical Analysis, University of Utrecht, Faculty of Pharmaceutical Sciences, Utrecht, The Netherlands

    I Meijerman, J. H. M. Schellens & J. H. Beijnen

Authors
  1. T. M. Bosch PhD PharmD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. V. D. Doodeman
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. P. H. M. Smits
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. I Meijerman
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. J. H. M. Schellens
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. J. H. Beijnen
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bosch, T.M., Doodeman, V.D., Smits, P.H.M. et al. Pharmacogenetic Screening for Polymorphisms in Drug-Metabolizing Enzymes and Drug Transporters in a Dutch Population. Mol Diag Ther 10, 175–185 (2006). https://doi.org/10.1007/BF03256456

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03256456

Keywords

Search

Navigation